Fungal Vaccine Development: State of the Art and Perspectives Using Immunoinformatics

Moisés Morais Inácio1,2, André Luís Elias Moreira1, Vanessa Rafaela Milhomem Cruz-Leite1

  • 1Laboratory of Molecular Biology, Institute of Biological Sciences, Federal University of Goiás, Goiânia 74605-170, Brazil.

Insights

Developing effective fungal vaccines remains a global health priority. This review highlights advances in immunotherapy and the crucial role of immunoinformatics in overcoming challenges for successful fungal vaccine development.

Area of Science:

  • Mycology
  • Immunology
  • Bioinformatics

Background:

  • Fungal infections pose a significant global health and economic burden.
  • Despite their effectiveness against other pathogens, no vaccines are currently approved for human fungal infections.
  • Developing antifungal vaccines is a critical unmet medical need.

Purpose of the Study:

  • To provide an updated overview of fungal vaccine development.
  • To review progress in immunotherapies against fungal infections.
  • To highlight the contribution of immunoinformatics to overcoming challenges in fungal vaccine design.

Main Methods:

  • Review of current literature on fungal vaccine development.
  • Analysis of methodological and experimental immunotherapies.
  • Exploration of advances in immunoinformatic tools and in silico approaches.

Main Results:

  • Significant research efforts are underway to develop fungal vaccines.
  • Immunoinformatics and in silico methods show promise in identifying vaccine candidates.
  • Methodological and experimental immunotherapies are advancing.

Conclusions:

  • Immunoinformatics offers powerful tools to address key challenges in developing effective fungal vaccines.
  • Continued research integrating computational approaches is essential for progress.
  • Successful development of fungal vaccines could significantly impact global health.

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
433
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
366
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.0K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
68